Pipeline biosimilar for asthma meets primary endpoint in P2/3 study


In Brief

Biosimilar News reports that Sorrento’s experimental anti-IgE biosimilar, STI-004, met it’s primary endpoint in a 32-week, Phase 2/3 study conducted in China. ?Patients who received?STI-004 experienced?asthma exacerbation at a lower rate than those who received placebo: ?21% vs?55%.

According to the Sorrento press release, the patient population included both?adult and adolescents suffering from allergic asthma.

Adverse Experiences

The Biosimilar News article and Sorrento press release reported?that the adverse events (AEs) experienced during the study were similar to those reported for the?currently marketed product, Xolair?. ?However, AEs for?STI-004 and?PBO that were?observed?during the study were not reported.